Hemogenyx Pharmaceuticals PLC Market Cap ($371.82K)
Market Cap & Net Worth: Hemogenyx Pharmaceuticals PLC (HEMO)
Hemogenyx Pharmaceuticals PLC market cap. Hemogenyx Pharmaceuticals PLC (LSE:HEMO) has a market capitalization of $371.82K (GBX3.06 Billion) as of November 7, 2026. Listed on the LSE stock exchange, this UK-based company holds position #31165 globally and #956 in its home market, demonstrating a -16.18% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Hemogenyx Pharmaceuticals PLC's stock price GBX570.00 by its total outstanding shares 5361267 (5.36 Million). Also see Hemogenyx Pharmaceuticals PLC (HEMO) cash flow conversion for how efficiently the company converts equity into cash flow.
Hemogenyx Pharmaceuticals PLC Market Cap History (2015–2026)
Hemogenyx Pharmaceuticals PLC market cap history from 2015 to 2026. Data shows growth from $2.45K to $371.82K (58.88% CAGR). Check Hemogenyx Pharmaceuticals PLC share price for real-time trading data and today's change.
Hemogenyx Pharmaceuticals PLC Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Hemogenyx Pharmaceuticals PLC's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset momentum of Hemogenyx Pharmaceuticals PLC to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.36x
Hemogenyx Pharmaceuticals PLC's market cap is 0.36 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $2.45K | $6.85K | -$180.88K | 0.36x | N/A |
Competitor Companies of HEMO by Market Capitalization
Companies near Hemogenyx Pharmaceuticals PLC in the global market cap rankings as of November 7, 2026. Also see HEMO current and non-current assets for a full breakdown of the balance sheet.
Key companies related to Hemogenyx Pharmaceuticals PLC by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #177 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #363 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #403 globally with a market cap of $69.36 Billion USD ( AU$98.02 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #177 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $547.09 |
| #363 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $904.35 |
| #403 | CSL Ltd | AU:CSL | $69.36 Billion | AU$202.04 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $254.19 |
Market Capitalization of Hemogenyx Pharmaceuticals PLC (2015–2026)
Market capitalization of Hemogenyx Pharmaceuticals PLC from 2015 to today. Between 2015 and today, Hemogenyx Pharmaceuticals PLC's market cap moved from $2.45K to $ 371.82K, with a yearly change of 58.88%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | GBX371.82K | -0.35% |
| 2025 | GBX373.12K | +41.23% |
| 2024 | GBX264.19K | +17508.70% |
| 2023 | GBX1.50K | +73.58% |
| 2022 | GBX864.31 | -23.19% |
| 2021 | GBX1.13K | -82.12% |
| 2020 | GBX6.29K | +394.87% |
| 2019 | GBX1.27K | -7.14% |
| 2018 | GBX1.37K | -16.00% |
| 2017 | GBX1.63K | -33.33% |
| 2015 | GBX2.45K | -- |
End of Day Market Cap According to Different Sources
On Nov 7th, 2026 the market cap of Hemogenyx Pharmaceuticals PLC was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $371.82K USD |
| MoneyControl | $371.82K USD |
| MarketWatch | $371.82K USD |
| marketcap.company | $371.82K USD |
| Reuters | $371.82K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Hemogenyx Pharmaceuticals PLC
Hemogenyx Pharmaceuticals Plc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of treatments for blood cancer. The company's lead product candidate is the HG-CT-1 therapy for the treatment of relapsed or refractory acute myeloid leukemia. It also develops chimeric bait receptor to treat viral infections derived and for certain cancer and neurol… Read more